Successful Pregnancies During Crizotinib Therapy for Anaplastic Lymphoma Kinase Positive Lymphoma

Overview

Journal Hematol Oncol

Date 2025 Jan 14

PMID 39809726

Authors

Veronica Guglielmana

Francesco Maria Fusi

Valentina Giardini

Federica Cocito

Carlo Gambacorti-Passerini

Affiliations

Soon will be listed here.

Abstract

Anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma (ALCL) typically affects young individuals and, despite high responsiveness to cytotoxic drugs, relapses occur in over 50% of patients. Crizotinib has improved outcomes, but its management in patients desiring parenthood remains an issue. This study presents the first description of four successful pregnancies during crizotinib treatment for ALK+ALCL: a female patient achieving two pregnancies through assisted reproductive technologies (ART), temporarily discontinuing crizotinib and maintaining a complete remission (CR), and a male patient conceiving naturally while on continuous therapy. These cases demonstrate crizotinib potential to support conception without compromising disease control, even in the absence of specific guidelines on treatment discontinuation.

References

Roelofsen D, Van Hove H, Bukkems V, Russel F, Eliesen G, Greupink R . Predicting fetal exposure of crizotinib during pregnancy: Combining human ex vivo placenta perfusion data with physiologically-based pharmacokinetic modeling. Toxicol In Vitro. 2022; 85:105471. DOI: 10.1016/j.tiv.2022.105471. View

Bousfiha A, Riahi Z, Elkhattabi L, Bakhchane A, Charoute H, Snoussi K . Further Evidence for the Implication of the MET Gene in Non-Syndromic Autosomal Recessive Deafness. Hum Hered. 2019; 84(3):109-116. DOI: 10.1159/000503450. View

Falini B, Pileri S, Zinzani P, Carbone A, Zagonel V, Verhoef G . ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999; 93(8):2697-706. View

Eliesen G, Van Den Broek P, van den Heuvel J, Bilos A, Pertijs J, van Drongelen J . Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017; 157(2):500-509. DOI: 10.1093/toxsci/kfx063. View

Mussolin L, Damm-Welk C, Pillon M, Woessmann W . Minimal Disease Monitoring in Pediatric Non-Hodgkin's Lymphoma: Current Clinical Application and Future Challenges. Cancers (Basel). 2021; 13(8). PMC: 8071445. DOI: 10.3390/cancers13081907. View

Gritti G, Boschini C, Rossi A, Delaini F, Grassi A, Algarotti A . Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas. PLoS One. 2015; 10(3):e0121822. PMC: 4376730. DOI: 10.1371/journal.pone.0121822. View

Passerini C, Farina F, Stasia A, Redaelli S, Ceccon M, Mologni L . Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst. 2014; 106(2):djt378. DOI: 10.1093/jnci/djt378. View

Padrao E, Melo C, Fernandes G, Magalhaes A . Lung cancer in pregnancy - Report of a case treated with crizotinib. Pulmonology. 2018; 24(3):205-207. DOI: 10.1016/j.pulmoe.2018.03.007. View

Tsuyama N, Sakamoto K, Sakata S, Dobashi A, Takeuchi K . Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. J Clin Exp Hematop. 2017; 57(3):120-142. PMC: 6144189. DOI: 10.3960/jslrt.17023. View

10.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

11.

Rindone G, Aroldi A, Bossi E, Verga L, Zambrotta G, Tarantino S . A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas. Blood Adv. 2022; 7(3):314-316. PMC: 9898594. DOI: 10.1182/bloodadvances.2022007538. View

12.

Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T . Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018; 93(5):607-614. PMC: 5947833. DOI: 10.1002/ajh.25043. View

13.

Gambacorti-Passerini C, Messa C, Pogliani E . Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011; 364(8):775-6. DOI: 10.1056/NEJMc1013224. View

14.

Mosse Y, Lim M, Voss S, Wilner K, Ruffner K, Laliberte J . Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013; 14(6):472-80. PMC: 3730818. DOI: 10.1016/S1470-2045(13)70095-0. View

15.

Jensen K, Persson G, Storgaard L, Nielsen B, Pedersen B, Maroun L . Antineoplastic treatment with crizotinib during pregnancy: a case report. Acta Oncol. 2018; 58(1):121-122. DOI: 10.1080/0284186X.2018.1497302. View